SCHEMBL6208856

SCHEMBL6208856

O=[N+]([O-])c1ccc(Oc2ccc3c(cnn3-c3cccnc3)c2)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.49
HSPB1 P04792 2/20 0.47
MAPT P10636 5/20 0.44
NPSR1 Q6W5P4 2/20 0.44
LMNA P02545 4/20 0.43
HTT P42858 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
GAA P10253 2/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SMO Q99835 1/20 0.41
KDR P35968 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 3/20 0.38
SCN9A Q15858 1/20 0.38
PPARG P37231 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6208447 0.83 HSPB1 (0.65) HSPB1MAPTNPSR1LMNAHTT
SCHEMBL6209189 0.83 CYP11B2 (0.53) CYP11B2ALDH1A1MEN1KMT2ASMO
SCHEMBL6208610 0.81 L3MBTL1 (0.49) CYP11B2HSPB1MAPTNPSR1LMNA
SCHEMBL6211088 0.78 HSPB1 (0.55) HSPB1MAPTNPSR1LMNAHTT
SCHEMBL9449031 0.76 LMNA (0.62) HSPB1MAPTNPSR1LMNAHTT
SCHEMBL6185201 0.74 CYP11B2 (0.59) CYP11B2LMNATDP1SMO
SCHEMBL6281960 0.74 CYP11B2 (0.59) CYP11B2NPSR1ALDH1A1MAPK1SMN1; SMN2
SCHEMBL6208908 0.74 SMO (0.48) CYP11B2MAPTMAPK1KMT2ASMO
SCHEMBL22529972 0.73 HSPB1 (0.61) CYP11B2HSPB1MAPTNPSR1LMNA
SCHEMBL6208246 0.73 MMP13 (0.59) CYP11B2SMOSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501833-B1 N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS PFIZER PROD INC (US) 2005-11-02 EP disclosed
US-6900201-B2 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-05-31 US disclosed
US-20040010141-A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040010141-A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP9, MMP8, MMP2 CYP11B2 579/4885HSPB1 1770/4885MAPT 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.